Physiological and Anatomical Alterations in Children with Liver Cirrhosis

Femke A Elzinga1,2, Samira Lier1, Paul R V Malik3

  • 1Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

Insights

Children with liver cirrhosis show physiological changes similar to adults, but hematocrit is notably lower in younger children. More pediatric data is needed for accurate physiologically based pharmacokinetic (PBPK) models.

Area of Science:

  • Pharmacokinetics
  • Pediatric Gastroenterology
  • Biomedical Modeling

Background:

  • Liver cirrhosis in children presents unique physiological and anatomical challenges.
  • Physiologically based pharmacokinetic (PBPK) models are crucial for understanding drug behavior in pediatric populations.
  • Existing PBPK models for liver cirrhosis are primarily based on adult data.

Purpose of the Study:

  • To evaluate physiological and anatomical changes in pediatric liver cirrhosis.
  • To inform the development of PBPK models for children with liver cirrhosis.
  • To identify age-specific differences in physiological parameters compared to adults.

Main Methods:

  • Conducted a literature review of studies on pediatric liver cirrhosis parameters (December 2023-May 2024).
  • Analyzed physiological and anatomical data, stratifying by age and disease severity (Child-Pugh, MELD/PELD).
  • Compared pediatric data with established adult PBPK model parameters.

Main Results:

  • Albumin, GFR, liver/renal blood flow, and cardiac index showed trends comparable to adults or lacked sufficient pediatric data.
  • Hematocrit was significantly lower in children aged 2 to <6 years (P=0.022), with a greater fractional decline than adults.
  • Developmental and nutritional factors may contribute to observed hematocrit differences.

Conclusions:

  • Pediatric liver cirrhosis shares some physiological trends with adults, but distinct age-specific differences exist.
  • Limited pediatric data hinders definitive conclusions for many parameters, impacting PBPK model accuracy.
  • Further age-specific research is essential to refine PBPK models and optimize pediatric drug therapy.
Abstract

Related Concept Videos

Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Liver Physiology01:30

Liver Physiology

The liver, an essential organ in the human body, performs over 200 vital functions that can be broadly categorized into metabolic, hematological, endocrine regulation, and bile production.
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of  70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can also...